DiaMedica Therapeutics Stock Forecast, Price & News

DiaMedica Therapeutics' stock was trading at $4.00 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, DMAC shares have increased by 43.8% and is now trading at $5.75.
View which stocks have been most impacted by COVID-19.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DiaMedica Therapeutics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for DiaMedica Therapeutics or view MarketBeat's top 5 stock picks.

Wall Street analysts have given DiaMedica Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but DiaMedica Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

DiaMedica Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, March 22nd 2021.
View our earnings forecast for DiaMedica Therapeutics.

DiaMedica Therapeutics Inc. (NASDAQ:DMAC) released its earnings results on Wednesday, November, 4th. The company reported ($0.19) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.15) by $0.04.
View DiaMedica Therapeutics' earnings history.

4 brokers have issued 1-year target prices for DiaMedica Therapeutics' shares. Their forecasts range from $14.00 to $16.00. On average, they expect DiaMedica Therapeutics' share price to reach $14.75 in the next year. This suggests a possible upside of 156.5% from the stock's current price.
View analysts' price targets for DiaMedica Therapeutics.

DiaMedica Therapeutics saw a increase in short interest in October. As of October 30th, there was short interest totaling 32,000 shares, an increase of 33.3% from the October 15th total of 24,000 shares. Based on an average daily volume of 45,100 shares, the days-to-cover ratio is currently 0.7 days.
View DiaMedica Therapeutics' Short Interest.

Some companies that are related to DiaMedica Therapeutics include Crinetics Pharmaceuticals (CRNX), Amryt Pharma (AMYT), UroGen Pharma (URGN), Avadel Pharmaceuticals (AVDL), Cogent Biosciences (UMRX), Aeglea BioTherapeutics (AGLE), Kala Pharmaceuticals (KALA), TherapeuticsMD (TXMD), Trevena (TRVN), Xenon Pharmaceuticals (XENE), Ovid Therapeutics (OVID), Affimed (AFMD), IDEAYA Biosciences (IDYA), Clovis Oncology (CLVS) and Cue Biopharma (CUE).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other DiaMedica Therapeutics investors own include VBI Vaccines (VBIV), Inovio Pharmaceuticals (INO), Dynavax Technologies (DVAX), Pfizer (PFE), Vaxart (VXRT), Aldeyra Therapeutics (ALDX), Capricor Therapeutics (CAPR), Oncolytics Biotech (ONCY), Sesen Bio (SESN) and Sorrento Therapeutics (SRNE).

(DMAC) raised $18 million in an IPO on Friday, December 7th 2018. The company issued 4,000,000 shares at $4.00-$5.00 per share. Craig-Hallum Capital Group served as the underwriter for the IPO.

DiaMedica Therapeutics trades on the NASDAQ under the ticker symbol "DMAC."

DiaMedica Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Stonepine Capital Management LLC (6.12%), Point72 Asset Management L.P. (4.27%), Nantahala Capital Management LLC (4.04%), Corriente Advisors LLC (3.90%), Granite Point Capital Management L.P. (3.45%) and Manatuck Hill Partners LLC (3.05%). Company insiders that own DiaMedica Therapeutics stock include Dietrich John Pauls, Harry W Alcorn Jr, Randall Michael Giuffre, Richard D Pilnik and Scott Kellen.
View institutional ownership trends for DiaMedica Therapeutics.

DMAC stock was bought by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Corriente Advisors LLC, Stonepine Capital Management LLC, Manatuck Hill Partners LLC, Granite Point Capital Management L.P., Boothbay Fund Management LLC, Worth Venture Partners LLC, and Nantahala Capital Management LLC. Company insiders that have bought DiaMedica Therapeutics stock in the last two years include Dietrich John Pauls, Harry W Alcorn Jr, Randall Michael Giuffre, Richard D Pilnik, and Scott Kellen.
View insider buying and selling activity for DiaMedica Therapeutics.

Shares of DMAC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of DMAC stock can currently be purchased for approximately $5.75.

DiaMedica Therapeutics has a market capitalization of $107.76 million and generates $500,000.00 in revenue each year. DiaMedica Therapeutics employs 8 workers across the globe.

The official website for DiaMedica Therapeutics is www.diamedica.com.

DiaMedica Therapeutics' mailing address is 2 CARLSON PARKWAY SUITE 260, MINNEAPOLIS MN, 55447. The company can be reached via phone at 763-312-6755 or via email at [email protected]